- Home
- LQDA vs PFLT Comparison
LQDA vs PFLT Comparison
Compare LQDA & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- PFLT
- Stock Information
- Founded
- LQDA 2004
- PFLT 2010
- Country
- LQDA United States
- PFLT United States
- Employees
- LQDA N/A
- PFLT N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- PFLT Finance: Consumer Services
- Sector
- LQDA Health Care
- PFLT Finance
- Exchange
- LQDA Nasdaq
- PFLT Nasdaq
- Market Cap
- LQDA 1.2B
- PFLT 1.1B
- IPO Year
- LQDA 2018
- PFLT N/A
- Fundamental
- Price
- LQDA $19.60
- PFLT $10.69
- Analyst Decision
- LQDA Strong Buy
- PFLT Buy
- Analyst Count
- LQDA 9
- PFLT 6
- Target Price
- LQDA $27.67
- PFLT $11.21
- AVG Volume (30 Days)
- LQDA 2.4M
- PFLT 666.6K
- Earning Date
- LQDA 08-06-2025
- PFLT 08-11-2025
- Dividend Yield
- LQDA N/A
- PFLT 11.48%
- EPS Growth
- LQDA N/A
- PFLT N/A
- EPS
- LQDA N/A
- PFLT 0.86
- Revenue
- LQDA $14,144,000.00
- PFLT $232,975,000.00
- Revenue This Year
- LQDA $189.27
- PFLT $45.12
- Revenue Next Year
- LQDA $402.79
- PFLT $9.18
- P/E Ratio
- LQDA N/A
- PFLT $12.42
- Revenue Growth
- LQDA N/A
- PFLT 49.56
- 52 Week Low
- LQDA $8.26
- PFLT $8.82
- 52 Week High
- LQDA $19.76
- PFLT $11.90
- Technical
- Relative Strength Index (RSI)
- LQDA 79.39
- PFLT 56.40
- Support Level
- LQDA $14.04
- PFLT $10.58
- Resistance Level
- LQDA $14.67
- PFLT $10.78
- Average True Range (ATR)
- LQDA 0.89
- PFLT 0.13
- MACD
- LQDA 0.70
- PFLT -0.01
- Stochastic Oscillator
- LQDA 97.88
- PFLT 52.50
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.